Skip to content

Shattuck Labs, Inc. STTK Capitalized R&D expense

Capitalized R&D expense at other companies

BillionToOne, Inc.
 logo
BillionToOne, Inc. BLLN
$6.06M-47.2%
ESAB logo
ESABESAB
$22.04M+7.2%
CorMedix logo
CorMedixCRMD
$36.28M
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$5.17M-73.7%
Curtiss-Wright logo
Curtiss-WrightCW
$52.53M-13.6%
Parker-Hannifin logo
Parker-HannifinPH
$172M+17.8%

Other financials

Income statement

See full
Revenue-
Operating income-$15.5M-8.0%
Net income-$14.8M-7.8%
EPS (diluted)-$0.13+51.9%

Balance sheet

See full
Cash & equivalents$90.4M+48.5%
Total debt$2.9M-9.5%
Total equity$95.8M+41.8%
Total assets$102.1M+32.3%

Cash flow

See full
Operating cash flow-$13.4M-11.6%
CapEx$63.0K
Free cash flow-$13.5M-12.1%

Valuation

See full
Market cap$564.45M+1,131%
Enterprise value$476.92M-4,119%
P/S564.5×+554×

Profitability

See full
Operating margin-5,266.4%-9,520pp
Net margin-4,987.4%-8,966pp
FCF margin-4,140.8%-7,144pp

Returns & leverage

See full
Return on equity-61%-8.0pp
Debt / equity0.0×
Current ratio22.1×+13.0×

Where this comes from

Reported directly by Shattuck Labs, Inc. in its filing.

Tagged under the XBRL concept sttk:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts.

The official record: Shattuck Labs, Inc.’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Shattuck Labs, Inc.'s capitalized r&d expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Shattuck Labs, Inc.'s capitalized r&d expense?
Shattuck Labs, Inc. (STTK) reported capitalized r&d expense of $29.42M in Q4 2025.
How has Shattuck Labs, Inc.'s capitalized r&d expense changed year-over-year?
Shattuck Labs, Inc.'s capitalized r&d expense decreased by 8.4% year-over-year, from $32.12M to $29.42M.
What does capitalized r&d expense mean?
This represents research and development expenditures that have been capitalized as assets on the balance sheet rather than expensed immediately. This accounting treatment reflects the long-term value of development projects and impacts the timing of tax deductions. It is a key indicator of how the company manages its R&D investment accounting and tax strategy.